Abbott Q2 Earnings Drop on Exact Sciences Acquisition Costs; Legal Overhang Persists
ABT sits 31% above its 52-week low of $81.97.
Summary
Abbott's Q2 2026 earnings dropped sharply due to costs tied to its Exact Sciences acquisition, while revenue grew 13%. Legal risks remain elevated after an appeals court upheld a $495 million NEC verdict.
Key Events · Earnings and Guidance · ABT
-
Earnings Decline on Acquisition Costs
Q2 net earnings fell 48% to $928M ($0.53 diluted EPS) from $1,779M ($1.01) a year ago, as higher interest expense ($351M vs $121M) and intangible amortization ($658M vs $420M) from the Exact Sciences deal weighed on profits.
-
Revenue Growth Driven by Exact Sciences
Total net sales rose 13% to $12.6B, with Diagnostic Products surging 42% to $3.1B, including $919M from the new Cancer Diagnostics unit. Medical Devices grew 9% to $5.9B.
-
Balance Sheet Transformation
Total assets jumped to $109.2B from $86.7B at year-end, with long-term debt soaring to $29.6B from $9.9B after issuing $20B in notes to fund the acquisition. Goodwill and intangibles increased to $52.5B.
-
Legal Setback in NEC Litigation
The Missouri Court of Appeals affirmed a $495M plaintiff verdict in the Gill NEC case. Abbott is seeking review by the Missouri Supreme Court. No reserves have been recorded for NEC cases due to uncertainty.
Analysis · ABT · Life Sciences
Abbott's Q2 net earnings fell 48% to $928 million, driven by higher interest expense and amortization from the $20.6 billion Exact Sciences acquisition. While revenue grew 13% to $12.6 billion, the bottom line was pressured by integration costs and a jump in debt. The balance sheet reflects the deal's full impact: long-term debt surged to $29.6 billion, and goodwill/intangibles nearly doubled. On the legal front, a Missouri appeals court affirmed a $495 million verdict in an NEC infant formula case, and Abbott is seeking further review. The company also settled a shareholder derivative lawsuit. These legal outcomes add uncertainty, though Abbott maintains no reserves for the NEC cases. The quarter underscores the near-term earnings drag from the transformative acquisition, even as the top line benefits from the new cancer diagnostics segment.
At the time of this filing, ABT was trading at $107.27 on NYSE in the Life Sciences sector, with a market capitalization of approximately $186.8B. The 52-week trading range was $81.97 to $137.49. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.